Pharma Mar, S.A. (PHMMF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Pharma Mar, S.A. (PHMMF) trades at $79.49 with AI Score 61/100 (Grade B+). Pharma Mar, S. A. is a Spanish biopharmaceutical company focused on oncology and RNA interference. Market cap: $1.38B, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for PHMMF: PHMMF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PHMMF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
PHMMF: 2/4 perspectives are bullish. Dominant signal: Moon AI bullish.
How is this calculated? →Pharma Mar, S.A. (PHMMF) Healthcare & Pipeline Overview
Pharma Mar, S.A., a Spanish biopharmaceutical company, researches, develops, and commercializes marine-derived anti-cancer drugs. Its portfolio includes approved treatments like Yondelis and Zepzelca, along with a pipeline targeting various solid tumors and RNA interference therapies, positioning it within the competitive oncology market.
What Is the Investment Thesis for PHMMF?
Pharma Mar's investment thesis rests on its established oncology portfolio, particularly Yondelis and Zepzelca, which generate revenue and provide a foundation for future growth. The company's pipeline of clinical-stage assets, including Ecubectedin and SYL1801, represents significant upside potential if approved. Key value drivers include successful clinical trial outcomes, regulatory approvals, and expansion into new markets. The company's expertise in marine-derived drug discovery provides a competitive advantage. However, potential risks include clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies. Investors should monitor the progress of Pharma Mar's clinical trials and regulatory submissions to assess the company's long-term growth prospects. The current market capitalization of $1.38B reflects the market's assessment of these factors.
Based on FMP financials and quantitative analysis
PHMMF Key Highlights
- Pharma Mar commercializes Yondelis for soft tissue sarcoma and recurrent ovarian cancer.
- Zepzelca is approved for the treatment of metastatic small cell lung cancer.
- The company has a pipeline of clinical-stage assets, including Ecubectedin (PM14) in Phase I/II trials.
- Pharma Mar is developing Aplidin for relapsed multiple myeloma.
- The company operates in the Oncology and RNA Interference segments.
Who Are PHMMF's Competitors?
PHMMF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| JNJ Johnson & Johnson | $258.13 | -1.87% | $621.38B | 90 |
| MRK Merck & Co., Inc. | $126.78 | -2.15% | $313.12B | 83 |
| BMY Bristol-Myers Squibb Company | $56.73 | -2.40% | $115.86B | 88 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PHMMF's Key Strengths?
- Unique marine-derived drug discovery platform
- Approved products with established revenue streams
- Strong pipeline of clinical-stage assets
- Experienced management team
What Are PHMMF's Weaknesses?
- Reliance on a limited number of products
- High research and development costs
- Dependence on regulatory approvals
- Competition from larger pharmaceutical companies
What Could Drive PHMMF Stock Higher?
- Clinical trial results for Ecubectedin (PM14) in advanced solid tumors.
- Regulatory submissions for new indications of Zepzelca.
- Expansion of commercial partnerships in new geographic markets.
- Progress in the development of RNA interference therapies.
- Continued revenue growth from existing products.
What Are the Key Risks for PHMMF?
- Clinical trial failures for pipeline assets.
- Regulatory setbacks or delays in approvals.
- Competition from established pharmaceutical companies.
- High research and development costs.
- Dependence on a limited number of products.
What Are the Growth Opportunities for PHMMF?
- Expansion of Zepzelca's indications: Zepzelca is currently approved for metastatic small cell lung cancer. Exploring and securing approvals for additional indications, such as other lung cancer subtypes or related malignancies, could significantly expand its market reach and revenue potential. The market for lung cancer therapeutics is substantial, projected to reach billions of dollars in the coming years. This expansion could occur within the next 3-5 years, contingent on successful clinical trials.
- Advancement of Ecubectedin (PM14): Ecubectedin is currently in Phase I/II clinical trials for advanced solid tumors. Positive trial results and subsequent regulatory approval could position Ecubectedin as a valuable treatment option for a range of cancers. The advanced solid tumor market represents a multi-billion dollar opportunity, with ongoing demand for novel therapies. This growth opportunity could materialize in the next 5-7 years, pending clinical and regulatory milestones.
- Development of RNA Interference Therapies: Pharma Mar's research into RNA interference offers the potential to develop novel therapeutics that silence gene expression. This approach could be applied to a wide range of diseases, including cancer and other genetic disorders. The RNAi therapeutics market is rapidly growing, driven by advancements in delivery technologies and increasing understanding of gene regulation. This growth opportunity is longer-term, potentially yielding results in 7-10 years.
- Geographic Expansion: Pharma Mar currently operates in key markets like Spain, China, Germany, Ireland, France, the rest of the European Union, and the United States. Expanding into new geographic regions, particularly emerging markets with growing healthcare infrastructure, could drive revenue growth. These markets often have unmet medical needs and increasing demand for innovative therapies. This expansion could be pursued within the next 3-5 years.
- Strategic Partnerships and Acquisitions: Pharma Mar could pursue strategic partnerships or acquisitions to expand its pipeline, access new technologies, or strengthen its market position. Collaborating with other biotech or pharmaceutical companies could accelerate the development and commercialization of its assets. The biotechnology industry is characterized by frequent mergers and acquisitions, providing opportunities for Pharma Mar to enhance its capabilities and expand its reach. This is an ongoing opportunity.
What Opportunities Does PHMMF Have?
- Expansion of existing product indications
- Development of new RNA interference therapies
- Geographic expansion into emerging markets
- Strategic partnerships and acquisitions
What Threats Does PHMMF Face?
- Clinical trial failures
- Regulatory setbacks
- Competition from generic drugs
- Changes in healthcare regulations
What Are PHMMF's Competitive Advantages?
- Proprietary marine-derived drug discovery platform.
- Patents protecting its key products and technologies.
- Established commercial infrastructure in key markets.
- Clinical and regulatory expertise in oncology.
What Does PHMMF Do?
Pharma Mar, S.A., founded in 1986 and headquartered in Madrid, Spain, is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies derived from marine organisms. The company operates through two primary segments: Oncology and RNA Interference. Pharma Mar's oncology portfolio includes Yondelis (trabectedin), a synthetic compound approved for the treatment of soft tissue sarcoma and recurrent ovarian cancer in various regions, and Zepzelca (lurbinectedin), a synthetic compound indicated for metastatic small cell lung cancer. Aplidin (plitidepsin) is another key asset, extracted from ascidians and being developed for relapsed multiple myeloma. Beyond marketed products, Pharma Mar has a robust pipeline of clinical-stage assets, including Ecubectedin (PM14), PM534, PM54, and SYL1801, targeting a range of solid tumors and ophthalmic diseases. The company's research extends to RNA interference, focusing on developing therapeutics that silence gene expression. Pharma Mar has a global presence, commercializing its products through partnerships and direct sales in key markets like Spain, China, Germany, Ireland, France, the rest of the European Union, and the United States.
What Products and Services Does PHMMF Offer?
- Research and develop anti-cancer drugs derived from marine organisms.
- Commercialize Yondelis for the treatment of soft tissue sarcoma and recurrent ovarian cancer.
- Develop Zepzelca for the treatment of metastatic small cell lung cancer.
- Conduct clinical trials to evaluate the safety and efficacy of new drug candidates.
- Research and develop RNA interference therapies.
- Manufacture and sell pharmaceutical products.
- Partner with other companies to commercialize their products in specific regions.
How Does PHMMF Make Money?
- Develop and commercialize proprietary drugs.
- Generate revenue through product sales.
- Out-license or partner for commercialization in certain territories.
- Invest in research and development to discover new drug candidates.
What Industry Does PHMMF Operate In?
The biotechnology industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. Pharma Mar operates within the oncology segment, which is experiencing significant growth due to the increasing prevalence of cancer and advancements in treatment options. The company's focus on marine-derived compounds provides a unique approach to drug discovery, differentiating it from competitors relying on traditional synthetic or biological methods. The market is competitive, with established pharmaceutical companies and smaller biotech firms vying for market share. Pharma Mar's success depends on its ability to successfully navigate the regulatory landscape, secure approvals for its pipeline assets, and effectively commercialize its products.
Who Are PHMMF's Key Customers?
- Oncologists
- Hospitals
- Patients with cancer
- Pharmaceutical distributors
FY2026 estForward Outlook
Wall Street analysts project Pharma Mar, S.A. revenue of about $205.2M for fiscal 2026, with EPS near $2.03. The estimate reflects 8 contributing analysts.
F-Score 8/9Financial Health
Pharma Mar, S.A.'s Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 7.86 places it in the safe zone, indicating low near-term bankruptcy risk.
ROE 36%Key Financial Metrics
Return on equity for Pharma Mar, S.A. stands at 35.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 20.9%, showing how much profit it generates from its asset base. PHMMF trades at a trailing price-to-earnings ratio of 17.02, below the Healthcare sector average of ~23x. Its free cash flow yield is 4.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.06 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 5.9%, the inverse of the P/E and a quick read on earnings relative to price.
Pharma Mar, S.A. (PHMMF) Valuation Context
Valued at $1.38B, PHMMF is classified as a small-cap stock. Relative to its peer group, PHMMF's quantitative score of 61/100 is below the peer average of 84/100.
Company Profile
Pharma Mar, S.A. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Madrid, ES. The company is led by CEO Jose Maria Fernandez Sousa-Faro. PHMMF has traded publicly since 2016.
PHMMF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Pharma Mar's oncology focus is gaining traction, especially with recent discussions around its pipeline drugs in the community.
- Insider activity suggests confidence; recent buys could signal positive expectations for upcoming trials.
- The community is buzzing about potential partnerships, indicating belief in Pharma Mar's innovative research.
- Positive market perception is growing as discussions highlight the unmet need Pharma Mar aims to address in cancer treatment.
Bear Case
- Community concerns persist regarding regulatory hurdles and approval timelines for key drugs.
- Bearish sentiment stems from worries about competition in the oncology space from larger, established players.
- Recent market developments suggest increased scrutiny of smaller biotech firms, impacting investor confidence in Pharma Mar.
- Discussions indicate skepticism about the commercial viability of some pipeline drugs, despite promising early results.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
PHMMF Latest News
No recent news available for PHMMF.
PHMMF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PHMMF.
Price Targets
Wall Street price target analysis for PHMMF.
PHMMF MoonshotScore
What does this score mean?
The MoonshotScore rates PHMMF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
PHMMF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Pharma Mar, S.A. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies on this tier may have limited financial information available, and trading activity can be sporadic. This tier contrasts with exchanges like the NYSE or NASDAQ, which have stringent listing standards regarding financial performance, corporate governance, and market capitalization. Investing in companies on the OTC Other tier carries higher risks due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure
- Low trading volume and liquidity
- Potential for price volatility
- Higher risk of fraud or manipulation
- Limited regulatory oversight
- Verify the company's financial statements.
- Research the company's management team and board of directors.
- Assess the company's business model and competitive landscape.
- Review the company's regulatory filings and compliance history.
- Evaluate the company's legal and operational risks.
- Monitor trading volume and price volatility.
- Consult with a qualified financial advisor.
- Established business operations in multiple countries
- Development of approved pharmaceutical products
- Ongoing clinical trials and research activities
- Presence of patents protecting its technologies
- Listing on the OTC market, even at the Other tier, indicates some level of public availability
Common Questions About PHMMF (Healthcare)
What does Pharma Mar, S.A. do?
Pharma Mar, S.A. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies derived from marine organisms. The company's primary focus is on oncology, with marketed products like Yondelis and Zepzelca used to treat various cancers. Additionally, Pharma Mar is actively involved in research and development of RNA interference therapies, aiming to silence gene expression for therapeutic purposes. Their business model centers around developing proprietary drugs, generating revenue through product sales, and out-licensing or partnering for commercialization in specific territories.
What are the main risks for PHMMF?
Pharma Mar faces several risks inherent to the biotechnology industry. Clinical trial failures represent a significant risk, as the company's pipeline assets may not demonstrate sufficient efficacy or safety. Regulatory setbacks or delays in approvals could also impede the commercialization of new products. Competition from established pharmaceutical companies with greater resources and broader product portfolios poses a challenge. Additionally, high research and development costs and dependence on a limited number of products could impact the company's financial performance.
How does Pharma Mar, S.A. navigate regulatory approval processes?
Pharma Mar, S.A. navigates regulatory approval processes by conducting rigorous clinical trials to demonstrate the safety and efficacy of its drug candidates. The company prepares comprehensive regulatory submissions to agencies like the FDA in the United States and the EMA in Europe, including detailed data on preclinical studies, clinical trial results, manufacturing processes, and risk-benefit assessments. Pharma Mar also maintains ongoing communication with regulatory agencies to address any questions or concerns and ensure compliance with applicable regulations. The success of their regulatory strategy is crucial for bringing new therapies to market.
What are the key growth opportunities for PHMMF in healthcare?
Key growth opportunities for Pharma Mar, S.A. lie in expanding the indications for its existing products, such as Zepzelca, into other cancer types. Advancing its pipeline of clinical-stage assets, including Ecubectedin and RNA interference therapies, represents another significant growth driver. Geographic expansion into emerging markets with unmet medical needs also presents a valuable opportunity. Furthermore, strategic partnerships and acquisitions could enhance Pharma Mar's pipeline, technology, and market reach. These opportunities align with the overall growth trends in the healthcare and biotechnology sectors.
What are the key factors to evaluate for PHMMF?
Pharma Mar, S.A. (PHMMF) holds an AI score of 61/100 (moderate). Not financial advice.
How frequently does PHMMF data refresh on this page?
PHMMF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven PHMMF's recent stock price performance?
Pharma Mar, S.A. (PHMMF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Unique marine-derived drug discovery platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PHMMF overvalued or undervalued right now?
Valuing Pharma Mar, S.A. (PHMMF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for PHMMF, limiting complete insights.
- OTC market data may have limited reliability.